Liver Function Changes in Patients with Hepatocellular Carcinoma Treated with Lenvatinib: Predictive Factors of Progression to Child-Pugh Class B, the Formation of Ascites and the Candidates for the Post-Progression Treatment

Liver Function Changes in Patients with Hepatocellular Carcinoma Treated with Lenvatinib: Predictive Factors of Progression to Child-Pugh Class B, the Formation of Ascites and the Candidates for the Post-Progression Treatment

The aim of this multicenter retrospective study was to assess the change in liver function in patients with hepatocellular carcinoma treated with lenvatinib. Among 139 consecutive patients receiving lenvatinib treatment between March 2018 and July 2019, 28 patients with Child-Pugh class B and one pa...

Full description

Bibliographic Details
Main Authors: Takeshi Hatanaka, Satoru Kakizaki, Tamon Nagashima, Masashi Namikawa, Takashi Ueno, Hiroki Tojima, Daichi Takizawa, Atsushi Naganuma, Hirotaka Arai, Ken Sato, Norifumi Harimoto, Ken Shirabe, Toshio Uraoka
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Cancers
Subjects:
hepatocellular carcinoma
liver function
albumin-bilirubin grade
lenvatinib
ramucirumab
Online Access:https://www.mdpi.com/2072-6694/12/10/2906

Similar Items

Similar Items